Ikena Oncology, Inc. (IKNA)
NASDAQ: IKNA · Real-Time Price · USD
1.710
-0.020 (-1.16%)
Nov 22, 2024, 4:00 PM EST - Market closed

Ikena Oncology Statistics

Total Valuation

Ikena Oncology has a market cap or net worth of $82.52 million. The enterprise value is -$47.12 million.

Market Cap 82.52M
Enterprise Value -47.12M

Important Dates

The last earnings date was Thursday, November 7, 2024, before market open.

Earnings Date Nov 7, 2024
Ex-Dividend Date n/a

Share Statistics

Ikena Oncology has 48.26 million shares outstanding. The number of shares has increased by 24.03% in one year.

Current Share Class 41.89M
Shares Outstanding 48.26M
Shares Change (YoY) +24.03%
Shares Change (QoQ) n/a
Owned by Insiders (%) 2.52%
Owned by Institutions (%) 22.83%
Float 13.87M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 124.97
Forward PS n/a
PB Ratio 0.61
P/TBV Ratio 0.61
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 15.32, with a Debt / Equity ratio of 0.06.

Current Ratio 15.32
Quick Ratio 14.94
Debt / Equity 0.06
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -37.08% and return on invested capital (ROIC) is -23.54%.

Return on Equity (ROE) -37.08%
Return on Assets (ROA) -22.06%
Return on Capital (ROIC) -23.54%
Revenue Per Employee $15,326
Profits Per Employee -$1.39M
Employee Count 43
Asset Turnover 0.00
Inventory Turnover n/a

Taxes

Income Tax -63,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +6.88% in the last 52 weeks. The beta is 0.49, so Ikena Oncology's price volatility has been lower than the market average.

Beta (5Y) 0.49
52-Week Price Change +6.88%
50-Day Moving Average 1.71
200-Day Moving Average 1.58
Relative Strength Index (RSI) 49.84
Average Volume (20 Days) 59,905

Short Selling Information

The latest short interest is 129,885, so 0.27% of the outstanding shares have been sold short.

Short Interest 129,885
Short Previous Month 147,782
Short % of Shares Out 0.27%
Short % of Float 0.94%
Short Ratio (days to cover) 3.02

Income Statement

In the last 12 months, Ikena Oncology had revenue of $659,000 and -$59.60 million in losses. Loss per share was -$1.24.

Revenue 659,000
Gross Profit -39.91M
Operating Income -64.29M
Pretax Income -66.78M
Net Income -59.60M
EBITDA -63.58M
EBIT -64.29M
Loss Per Share -$1.24
Full Income Statement

Balance Sheet

The company has $138.03 million in cash and $8.39 million in debt, giving a net cash position of $129.64 million or $2.69 per share.

Cash & Cash Equivalents 138.03M
Total Debt 8.39M
Net Cash 129.64M
Net Cash Per Share $2.69
Equity (Book Value) 134.23M
Book Value Per Share 2.78
Working Capital 132.29M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$61.56 million and capital expenditures -$262,000, giving a free cash flow of -$61.83 million.

Operating Cash Flow -61.56M
Capital Expenditures -262,000
Free Cash Flow -61.83M
FCF Per Share -$1.28
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin -9,755.24%
Pretax Margin -9,053.41%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin -3,939.43%

Dividends & Yields

Ikena Oncology does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -24.03%
Shareholder Yield -24.03%
Earnings Yield -72.22%
FCF Yield -74.92%

Analyst Forecast

The average price target for Ikena Oncology is $3.00, which is 75.44% higher than the current price. The consensus rating is "Buy".

Price Target $3.00
Price Target Difference 75.44%
Analyst Consensus Buy
Analyst Count 2
Revenue Growth Forecast (5Y) 36.14%
EPS Growth Forecast (5Y) -12.74%
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Ikena Oncology has an Altman Z-Score of 0.17 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 0.17
Piotroski F-Score 1